MedPath

PFIZER INC.

PFIZER INC. logo
🇺🇸United States
Ownership
Public
Established
1849-01-01
Employees
88K
Market Cap
$163.3B
Website
http://www.pfizer.com

A Multiple Dose Study Of PF-06678552 In Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2014-03-06
Last Posted Date
2014-07-31
Lead Sponsor
Pfizer
Target Recruit Count
38
Registration Number
NCT02079922
Locations
🇧🇪

Pfizer Investigational Site, Brussels, Belgium

A Study Of PF-06647263 In Patients With Advanced Solid Tumors

Phase 1
Terminated
Conditions
Neoplasms
Triple-Negative Breast Cancer
Interventions
First Posted Date
2014-03-05
Last Posted Date
2019-04-29
Lead Sponsor
Pfizer
Target Recruit Count
60
Registration Number
NCT02078752
Locations
🇺🇸

Huntsman Cancer Hospital / University of Utah, Salt Lake City, Utah, United States

🇺🇸

Huntsman Cancer Institute-University of Utah, Salt Lake City, Utah, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

and more 7 locations

A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06372865 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) and Aged 56-75 Years (Group 2)

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2014-02-25
Last Posted Date
2014-08-18
Lead Sponsor
Pfizer
Target Recruit Count
50
Registration Number
NCT02070289
Locations
🇧🇪

Pfizer Investigational Site, Brussels, Belgium

Study To Evaluate Safety And Tolerability Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2014-02-25
Last Posted Date
2018-11-14
Lead Sponsor
Pfizer
Target Recruit Count
72
Registration Number
NCT02070939
Locations
🇺🇸

New Haven Clinical Research Unit, New Haven, Connecticut, United States

A Study To Investigate Palbociclib (PD-0332991) Pharmacokinetics In Healthy Subjects Of Japanese Descent Relative To Healthy Non-Asian Subjects, And To Determine If Changes In Palbociclib Dose Result In Proportional Changes In Palbociclib Plasma Exposure In Japanese Subjects

First Posted Date
2014-02-11
Last Posted Date
2014-06-24
Lead Sponsor
Pfizer
Target Recruit Count
27
Registration Number
NCT02059330
Locations
🇺🇸

Pfizer Investigational Site, New Haven, Connecticut, United States

A Drug Interaction Study Between Bosutinib And Aprepitant In Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2014-02-10
Last Posted Date
2014-06-24
Lead Sponsor
Pfizer
Target Recruit Count
20
Registration Number
NCT02058277
Locations
🇺🇸

Pfizer Investigational Site, DeLand, Florida, United States

A Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy

Phase 2
Completed
Conditions
LMNA-Related Dilated Cardiomyopathy
Interventions
Drug: ARRY-371797, p38 inhibitor; oral
First Posted Date
2014-02-07
Last Posted Date
2020-10-14
Lead Sponsor
Pfizer
Target Recruit Count
12
Registration Number
NCT02057341
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

🇺🇸

The Ohio State University, Columbus, Ohio, United States

🇺🇸

Johns Hopkins University, Baltimore, Maryland, United States

and more 3 locations

Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects

Phase 2
Completed
Conditions
Hypercholesterolemia
Interventions
First Posted Date
2014-02-05
Last Posted Date
2019-02-08
Lead Sponsor
Pfizer
Target Recruit Count
218
Registration Number
NCT02055976
Locations
🇯🇵

Maebashi Hirosegawa Clinic, Maebashi, Gunma, Japan

🇯🇵

Heishinkai Medical Group Incorporated ToCROM Clinic, Shinjuku-ku, Tokyo, Japan

🇯🇵

Yokohama Minoru Clinic, Yokohama, Kanagawa, Japan

and more 6 locations

A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug On Adults With Type 2 Diabetes Mellitus Taking Metformin

Phase 2
Terminated
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: Placebo
First Posted Date
2014-02-03
Last Posted Date
2016-05-02
Lead Sponsor
Pfizer
Target Recruit Count
13
Registration Number
NCT02053103
Locations
🇺🇸

Pfizer Investigational Site, Orlando, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath